The mechanism of action of these immune checkpoint inhibitors is well understood: the inhibitory role of CTLA-4 and PD-L1 on the immune system, for instance, is exploited by the malignant cells to escape from the immune surveillance [11], hence, their blockade allows for a stronger response against the tumor. Here, CTLA4 is linked to neoplasm.